Lucid Diagnostics Stock Market Outlook
| LUCD Stock | USD 1.20 0.01 0.83% |
About 57% of Lucid Diagnostics' investor base is looking to short. The analysis of overall sentiment of trading Lucid Diagnostics stock suggests that many investors are alarmed at this time. The current market sentiment, together with Lucid Diagnostics' historical and current headlines, can help investors time the market. In addition, many technical investors use Lucid Diagnostics stock news signals to limit their universe of possible portfolio assets.
Comfort Level 43
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Lucid Diagnostics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Lucid Diagnostics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentWaiting |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Lucid Diagnostics is 'Cautious Hold'. Macroaxis provides Lucid Diagnostics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LUCD positions.
Execute Lucid Diagnostics Advice
The Lucid recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Lucid Diagnostics. Macroaxis does not own or have any residual interests in Lucid Diagnostics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Lucid Diagnostics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Mild | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Risky | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
For the selected time horizon Lucid Diagnostics has a Mean Deviation of 2.58, Semi Deviation of 2.68, Standard Deviation of 3.44, Variance of 11.85, Downside Variance of 10.14 and Semi Variance of 7.16We provide investment recommendation to complement the last-minute expert consensus on Lucid Diagnostics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the entity's potential to grow using all technical and fundamental data available at the time. To make sure Lucid Diagnostics is not overpriced, please verify all Lucid Diagnostics fundamentals, including its shares owned by insiders, gross profit, debt to equity, as well as the relationship between the price to book and cash and equivalents . Given that Lucid Diagnostics is a hitting penny stock territory we strongly suggest to closely look at its number of shares shorted.
Lucid Diagnostics Trading Alerts and Improvement Suggestions
| Lucid Diagnostics may become a speculative penny stock | |
| Lucid Diagnostics had very high historical volatility over the last 90 days | |
| Lucid Diagnostics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.35 M. Net Loss for the year was (45.53 M) with loss before overhead, payroll, taxes, and interest of (2.56 M). | |
| Lucid Diagnostics currently holds about 34.46 M in cash with (44.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.89. | |
| Lucid Diagnostics has a frail financial position based on the latest SEC disclosures | |
| Roughly 35.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from prnewswire.com: PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities |
Lucid Diagnostics Returns Distribution Density
The distribution of Lucid Diagnostics' historical returns is an attempt to chart the uncertainty of Lucid Diagnostics' future price movements. The chart of the probability distribution of Lucid Diagnostics daily returns describes the distribution of returns around its average expected value. We use Lucid Diagnostics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Lucid Diagnostics returns is essential to provide solid investment analysis for Lucid Diagnostics.
| Mean Return | 0.23 | Value At Risk | -4.72 | Potential Upside | 6.09 | Standard Deviation | 3.44 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Lucid Diagnostics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Lucid Stock Institutional Investors
| Shares | Goldman Sachs Group Inc | 2025-06-30 | 308.7 K | Renaissance Technologies Corp | 2025-06-30 | 243.3 K | Nuveen, Llc | 2025-06-30 | 243.3 K | Wells Fargo & Co | 2025-06-30 | 226.9 K | Xml Financial, Llc | 2025-06-30 | 178.8 K | Charles Schwab Investment Management Inc | 2025-06-30 | 174.9 K | Bank Of New York Mellon Corp | 2025-06-30 | 156.9 K | Barclays Plc | 2025-06-30 | 120 K | Squarepoint Ops Llc | 2025-06-30 | 112.2 K | Vanguard Group Inc | 2025-06-30 | 4.1 M | Blackrock Inc | 2025-06-30 | 3.6 M |
Lucid Diagnostics Cash Flow Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change In Cash | 53.5M | (31.2M) | (3.6M) | 3.5M | 3.1M | 2.6M | |
| Net Borrowings | 7.7M | 0.0 | 10M | 18.0M | 20.7M | 21.7M | |
| Free Cash Flow | (18.5M) | (30.6M) | (33.0M) | (44.8M) | (40.3M) | (38.3M) | |
| Other Non Cash Items | 9.6M | 653K | 4.9M | 119K | 136.9K | 130.0K | |
| Net Income | (28.1M) | (56.2M) | (52.7M) | (45.5M) | (41.0M) | (43.0M) | |
| End Period Cash Flow | 53.7M | 22.5M | 18.9M | 22.4M | 25.7M | 18.5M | |
| Change To Netincome | 173.9K | 65.5K | 9.6M | 13.9M | 15.9M | 16.7M | |
| Investments | (862K) | (4.1M) | (249K) | (646K) | (581.4K) | (610.5K) |
Lucid Diagnostics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Lucid Diagnostics or Health Care Equipment & Supplies sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Lucid Diagnostics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Lucid stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.18 | |
β | Beta against Dow Jones | 0.59 | |
σ | Overall volatility | 3.45 | |
Ir | Information ratio | 0.04 |
Lucid Diagnostics Volatility Alert
Lucid Diagnostics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Lucid Diagnostics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Lucid Diagnostics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Lucid Diagnostics Fundamentals Vs Peers
Comparing Lucid Diagnostics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Lucid Diagnostics' direct or indirect competition across all of the common fundamentals between Lucid Diagnostics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Lucid Diagnostics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Lucid Diagnostics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Lucid Diagnostics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Lucid Diagnostics to competition |
| Fundamentals | Lucid Diagnostics | Peer Average |
| Return On Equity | -3.31 | -0.31 |
| Return On Asset | -0.79 | -0.14 |
| Operating Margin | (9.71) % | (5.51) % |
| Current Valuation | 189.91 M | 16.62 B |
| Shares Outstanding | 131.1 M | 571.82 M |
| Shares Owned By Insiders | 35.35 % | 10.09 % |
| Shares Owned By Institutions | 29.11 % | 39.21 % |
| Number Of Shares Shorted | 7.01 M | 4.71 M |
| Price To Book | 2.16 X | 9.51 X |
| Price To Sales | 35.76 X | 11.42 X |
| Revenue | 4.35 M | 9.43 B |
| Gross Profit | (2.56 M) | 27.38 B |
| EBITDA | (44.34 M) | 3.9 B |
| Net Income | (45.53 M) | 570.98 M |
| Cash And Equivalents | 34.46 M | 2.7 B |
| Cash Per Share | 0.89 X | 5.01 X |
| Total Debt | 21.25 M | 5.32 B |
| Debt To Equity | 0.06 % | 48.70 % |
| Current Ratio | 4.55 X | 2.16 X |
| Book Value Per Share | (0.23) X | 1.93 K |
| Cash Flow From Operations | (44.14 M) | 971.22 M |
| Short Ratio | 3.02 X | 4.00 X |
| Earnings Per Share | (0.77) X | 3.12 X |
| Target Price | 3.79 | |
| Number Of Employees | 72 | 18.84 K |
| Beta | 1.22 | -0.15 |
| Market Capitalization | 157.32 M | 19.03 B |
| Total Asset | 30.71 M | 29.47 B |
| Retained Earnings | (203.77 M) | 9.33 B |
| Working Capital | 1.62 M | 1.48 B |
| Net Asset | 30.71 M |
Note: Disposition of tradable shares by Aklog Lishan of Lucid Diagnostics subject to Rule 16b-3 [view details]
Lucid Diagnostics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Lucid . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Lucid Diagnostics Buy or Sell Advice
When is the right time to buy or sell Lucid Diagnostics? Buying financial instruments such as Lucid Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Lucid Diagnostics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Banks Thematic Idea Now
Banks
Large and small money and credit banks and credit services. The Banks theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Lucid Diagnostics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Health Care Equipment & Supplies sector continue expanding? Could Lucid diversify its offerings? Factors like these will boost the valuation of Lucid Diagnostics. Expected growth trajectory for Lucid significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Lucid Diagnostics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth 0.033 | Return On Assets | Return On Equity |
Understanding Lucid Diagnostics requires distinguishing between market price and book value, where the latter reflects Lucid's accounting equity. The concept of intrinsic value - what Lucid Diagnostics' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Lucid Diagnostics' price substantially above or below its fundamental value.
Understanding that Lucid Diagnostics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Lucid Diagnostics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Lucid Diagnostics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.